Lv5
1544 积分 2022-10-21 加入
Epcoritamab plus rituximab, dexamethasone, cytarabine, oxaliplatin/carboplatin induces deep and durable responses in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma: results from the EPCORE NHL-2 trial
2小时前
求助中
Glofitamab Combined With Pola-R-CHP or R-CHOP as First Therapy in Younger Patients With High-Risk Large B-Cell Lymphoma: Results From the COALITION Study
2小时前
已完结
Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial
1个月前
已完结
Recent progress of black phosphorus quantum dots: Synthesis method, biological characteristics, and biomedical applications
2个月前
已完结
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study
3个月前
已完结
Garsorasib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial
4个月前
已完结
Neurofibromatosis type 1 system-based manifestations and treatments: a review
4个月前
已完结
Cutaneous manifestations in neurofibromatosis type 1
4个月前
已关闭
[Neurofibromatosis type 1: recent advances]
4个月前
已关闭
Targeting HER2 heterogeneity in breast and gastrointestinal cancers
4个月前
已完结
皖公网安备34019202002308